Cancer Vaccine Set to Replace Chemotherapy
BioNTech Founders Discuss Advances in Cancer Treatment
The founders of BioNTech, Prof. Dr. Özlem Türeci and Prof. Dr. Uğur Şahin, recently shared their insights on the progress of cancer research and the development of potential cancer vaccines in an interview with the German Focus magazine.
Prof. Şahin highlighted the significant strides made in cancer research, revealing that an antibody against lung cancer and a candidate drug for metastasized breast cancer have shown promise for approval. Additionally, he mentioned that ten vaccine candidates have completed phase 2 or phase 3 trials by the end of this year, indicating potential for registration. He also mentioned ongoing clinical research against a total of 30 types of cancer, with successful results being achieved. Prof. Şahin expressed the company’s ambition to develop a wide portfolio of cancer treatments by 2030.
Meanwhile, Prof. Türeci emphasized the groundbreaking advancements in the fight against cancer, underscoring BioNTech’s contributions to this progress. She stressed the importance of individualized cancer treatment, noting that each patient’s cancer cells are unique. Türeci mentioned that BioNTech is working towards a future where chemotherapy may not be necessary, and the body’s own defense system can effectively combat cancer. The use of antibody drug conjugates (ADCs) and vaccines, instead of chemotherapy, is a key element in their approach, with the potential to provide more precise and effective treatments in the future.
In summary, the co-founders of BioNTech highlighted the significant progress in the field of cancer treatment, expressing optimism about the possibility of more effective and individualized treatments in the future. Their commitment to pioneering research and innovation in cancer therapy offers hope for improved outcomes for patients battling this complex disease.
